Ask AI
ProCE Banner Activity

MATTERHORN: Phase III Trial of Durvalumab or Placebo + FLOT in Resectable Gastric and Gastroesophageal Junction Cancers

Conference Coverage
Slideset

In the double-blind, randomized phase III MATTERHORN trial, addition of durvalumab to perioperative FLOT in patients with gastric/GEJ cancers was associated with significantly improved event-free survival vs placebo + FLOT, with no new safety signals identified.

Released: June 05, 2025

Expiration: December 04, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Daiichi Sankyo, Inc. and Genentech, a member of the Roche Group.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group